At least one-third of the world's population has been infected with the hepatitis B virus (HBV), and 400 million people are chronic carriers. In most populations, chronic HBV infection is the ...

Use the tweezers to pull out a segment of DNA from the hepatitis B virus. A subunit vaccine makes use of just a small portion of a pathogen. For a virus, the vaccine can contain just a piece of ...

Researchers at Oregon Health & Science University have developed the first transgenic nonhuman primate model—genetically ...

The American Gastroenterology Association (AGA) updated its clinical practice guidelines for managing hepatitis B ...

With several drugs in use that inhibit the hepatitis B virus polymerases (nucleos(t)ide analogues (or NUCs)), some argue that new direct-acting antiviral drugs, and new NUCs in particular ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a ...

Existing treatment criteria for chronic hepatitis B virus (HBV) infection are mainly based on data from observational studies, such as the REVEAL study from Taiwan, which was initiated in the early ...